Navigation Links
Alnylam and Stanford University Scientists Discover New Role for,microRNAs (miRNAs) in T Cell Biology and Immunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 22, 2007 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today publication of a study in the journal Cell by Alnylam and Stanford University scientists on the role of miRNAs in immunity. In the pre-clinical study, a specific miRNA, miR-181a, was shown to play an important role in controlling T cell responsiveness to antigens by regulating the T cell receptor signaling pathway. Because the T cell response to antigens is one of the primary components of certain autoimmune disorders, these findings further validate miRNAs as disease targets and point to new potential therapeutic applications for antagomirs, a novel class of oligonucleotide-based inhibitors of specific miRNAs.

"Our research points to a critical role for miRNAs, specifically miR-181a, in the regulation of T cell biology," said Dr. Mark Davis from Stanford University School of Medicine, a senior author of the publication. "We're excited about this new discovery as it represents the first clear example of a role for miRNAs in the immune response to antigens."

"In our study, upward or downward modulation of miR-181a was found to control certain aspects of T cell development and to regulate T cell responses to antigens via the T cell receptor signaling pathway," said Dr. Chang-Zheng Chen, also from Stanford University School of Medicine and a senior author of the publication.

"Alnylam's research on miRNAs derives from our discovery of antagomirs, a novel class of oligonucleotide inhibitors of miRNAs. These reagents have become powerful tools to investigate the role of miRNAs in biology and disease processes. We are fortunate to collaborate with some of the leading labs across the world, such as our colleagues at Stanford, in our efforts to explore therapeutic opportunities for miRNA antagonists," said Dr. Muthiah Manoharan, Vice President, Drug Discovery
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
5. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
6. Once-Fatal Metabolic Disorders Treatable, Says Stanford/Packard Researcher
7. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
8. Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds
9. Stanford Study Finds No Conclusive Benefit From Treating Kleptomania With Medication
10. Study of Drug Therapy for Compulsive Buying Yields a Puzzle, Stanford Researcher Says
11. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
Post Your Comments:
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)... 19, 2013  Decision Resources, one of the ... and healthcare issues, finds that, for the treatment ... and European rheumatologists cite a therapy,s induction of ... influences their prescribing decisions. Over 60 percent and ... rank the percentage of patients achieving remission at ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") ... results for the first quarter ended March 31, 2011. ... million through two financings, advanced pixantrone into a confirmatory ... Therapeutics Ltd. ("Chroma") to co-develop and market Chroma,s drug ...
... April 26, 2011 BD (Becton, Dickinson and Company) ... technology company, today reported quarterly revenues of $1.922 billion ... representing an increase of 6.8 percent from the prior-year ... percent, despite an unfavorable comparison to the prior year ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6BD Announces Results for 2011 Second Fiscal Quarter 2BD Announces Results for 2011 Second Fiscal Quarter 3BD Announces Results for 2011 Second Fiscal Quarter 4BD Announces Results for 2011 Second Fiscal Quarter 5BD Announces Results for 2011 Second Fiscal Quarter 6BD Announces Results for 2011 Second Fiscal Quarter 7BD Announces Results for 2011 Second Fiscal Quarter 8BD Announces Results for 2011 Second Fiscal Quarter 9BD Announces Results for 2011 Second Fiscal Quarter 10BD Announces Results for 2011 Second Fiscal Quarter 11BD Announces Results for 2011 Second Fiscal Quarter 12BD Announces Results for 2011 Second Fiscal Quarter 13BD Announces Results for 2011 Second Fiscal Quarter 14
(Date:6/19/2013)... FL (PRWEB) June 19, 2013 At a ... the positive changes and growth that has occurred over the ... travel club. , Shuman said, "Travel Services has added vendors, ... heights beyond belief. Membership is up, even in the ... meet the demands of members." , Having been in the ...
(Date:6/19/2013)... In 2011, the value of the Serbian ... drugs form the largest sector, accounting for nearly one ... is a significant contributor to the local economy; it ... 50% of the total domestic chemical industry output fall ... and Zdravlje Actavis are key participants in the Serbian ...
(Date:6/19/2013)... the brink of extinction but can we finish the ... a Bristol academic addresses in his new book, published next ... University of Bristol, has produced the first comprehensive history of ... of polio explores the experiences of victims alongside the medical ... , According to a review by The Lancet ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Ultimate Medical ... Telethon, an 11.5-hour broadcast on WFLA News Channel 8. ... collected more than $84 million for All Children's Hospital ... event, themed "30 Years of Miracles," marked the second ... 18 UMA employees worked the phones during the Telethon, ...
(Date:6/19/2013)... Lexington, Mass. (PRWEB) June 19, 2013 ... IT security solutions, today announced that Imprivata OneSign ... KLAS® 2013 Mid-Term Performance Review: Software & Services ... by KLAS laud Imprivata on the superior performance of ... and support, and they indicate that Imprivata is integral ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Paralysed with fear: The story of polio 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... , ALLEGAN, Mich., Nov. 9 Perrigo Company (Nasdaq: ... C. Papa will present at the Credit Suisse 18th ... 11:00 p.m. (MT) at the Arizona Biltmore Hotel in ... global healthcare supplier that develops, manufactures and distributes OTC ...
... Simple computerized alerts can help curb the impulse ... study in the August issue of Journal ... clinicians received computerized alerts, which compared medication brands, ... heavily marketed sleep medications to comparable generic equivalents. ...
... Research carried out among thousands of people has shown ... mass, leading to osteoporosis and fractures. This was ... head of the Brain and Behavior Laboratory, and Prof. Itai ... the relationship between depression and bone loss is particularly strong ...
... the clock 8 years, research shows , MONDAY, Nov. 9 ... improves so much that most feel eight years younger, a new ... everyone except a small minority -- only 2 percent -- who ... "The results really say three things: That work puts an extra ...
... announced today the acquisition of App Tech Global, Inc., which ... Natural Nutrition,s name will be changed to App Tech, Corp. ... of App Tech Global, Inc. , App Tech is developing ... App Tech is focused on multi platform apps designed ...
... China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading pharmaceutical company,specializing in the development, manufacturing, and ... today announced an agreement,to acquire the manufacturing license ... Ltd. ("Tianda"). The acquisition of the,manufacturing license will ...
Cached Medicine News:Health News:Computerized support keeps prominence of name brand drugs at bay 2Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Retirement Brings Most a Big Health Boost 2Health News:Retirement Brings Most a Big Health Boost 3Health News:Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 2
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
10 L, Bulk Recommended for 5 and 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: